NCT06260553View on ClinicalTrials.gov

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

February 7, 2025

Study Completion Date

August 7, 2025

Conditions
EGFR/ ALK-negative Advanced NSCLC
Interventions
DRUG

tislelizumab and metronomic oral vinorelbine

tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.

Trial Locations (1)

Unknown

Fujian cancer hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV